Skip to content
Digitoxin
Crystodigin (digitoxin) is a small molecule pharmaceutical. Digitoxin was first approved as Crystodigin on 1982-01-01. It is used to treat anxiety disorders, atrial fibrillation, atrial flutter, cardiogenic shock, and heart failure amongst others in the USA. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anxiety disordersEFO_0006788D001008F41.1
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiogenic shock—D012770R57.0
heart failureEFO_0003144D006333I50
low cardiac output—D002303—
supraventricular tachycardiaHP_0004755D013617I47.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01A: Cardiac glycosides
— C01AA: Digitalis glycosides
— C01AA04: Digitoxin
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIGITOXIN
INNdigitoxin
Description
Digitoxin is a cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. It has a role as an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is functionally related to a digitoxigenin. It is a conjugate acid of a digitoxin(1-).
Classification
Small molecule
Drug classfluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
Identifiers
PDB7DDI
CAS-ID71-63-6
RxCUI3403
ChEMBL IDCHEMBL254219
ChEBI ID28544
PubChem CID441207
DrugBankDB01396
UNII IDE90NZP2L9U (ChemIDplus, GSRS)
Target
Agency Approved
ATP1A1
ATP1A1
Organism
Homo sapiens
Gene name
ATP1A1
Gene synonyms
NCBI Gene ID
476
Protein name
sodium/potassium-transporting ATPase subunit alpha-1
Protein synonyms
ATPase, Na+/K+ transporting, alpha 1 polypeptide, Na(+)/K(+) ATPase alpha-1 subunit, Na+/K+ ATPase 1, Na, K-ATPase, alpha-A catalytic polypeptide, Na,K-ATPase alpha-1 subunit, Na,K-ATPase catalytic subunit alpha-A protein, Sodium pump subunit alpha-1, sodium-potassium ATPase catalytic subunit alpha-1, sodium-potassium-ATPase, alpha 1 polypeptide
Uniprot ID
Q9UJ21
Mouse ortholog
Atp1a1 (11928)
sodium/potassium-transporting ATPase subunit alpha-1 (Q91Z09)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,601 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
29 adverse events reported
View more details